icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Boceprevir/Merck HCV Presentations - AASLD, IDSA
 
 
 
  • AASLD: Cost-Effectiveness of Boceprevir Use in Patients with Chronic Hepatitis C Genotype-1 Who Failed Prior Treatment with Peginterferon/Ribavirin - (11/28/11)
     
  • AASLD: Treatment Week 12/24 Stopping Rules for Boceprevir (BOC) Combination Therapy with Peginterferon+Ribavirin (PR): Exploratory Analyses of SPRINT-2 and RESPOND-2 - (11/22/11)
     
  • AASLD: In Vitro Assessment of Potential Drug-Drug Interactions Between Telaprevir and Cyclophilin Inhibitors in the Treatment of Chronic Hepatitis C - (11/22/11)
     
  • AASLD: An Evaluation of Neutropenia in the Pivotal Studies of Boceprevir Plus Peginterferon alfa-2b/Ribavirin - (11/22/11)
     
  • IDSA: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/25/11)

    AASLD: Overall Safety Profile of Boceprevir Plus Peginterferon alfa-2a/Ribavirin in Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin - (11/15/11)

    AASLD: Baseline Viral Voad Predicts SVR: Effect of Baseline Viral Load (VL) on Response of Boceprevir (BOC) Plus Peginterferon Alfa-2b/Ribavirin (PR) in Patients Infected With HCV Genotype 1 - (11/15/11)

    AASLD: MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity - (11/07/11)

    AASLD: Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4a Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients - (11/07/11)

    AASLD: Discovery of MK-4882, a Novel Inhibitor of HCV NS5a with an Attractive Pre-clinical Profile - (11/07/11)

    AASLD: ITPA Deficiency is Associated with Lower Rates of Anemia and EPO use in Patients Treated with Boceprevir (BOC) plus Peginterferon/Ribavirin (PR) - (11/20/11)

    AASLD: Influence of Hepatitis C Virus (HCV) Genotype-1 (G1) Subtype, Baseline Viral Load and IL28B Genotype on Peginterferon (PEG-IFN)/Ribavirin (RBV) Treatment Response: Results of the IDEAL Study - (11/16/11)

    AASLD: Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavirin: The PROVIDE Study - (11/16/11)

    AASLD: Once-Daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in Combination With Peginterferon Alfa-2b/Ribavirin (PR) for 12 Weeks Plus 12 Weeks PR in Treatment-Naive Patients With HCV Genotype 1 (G1): SVR Results From NEXT-1, a Phase 2 Study - (11/16/11)

    AASLD: In vitro Assessment of Drug-Drug Interaction Potential of Boceprevir As an Inhibitor and Inducer of Drug Metabolizing Enzymes and Transporters - (11/16/11)

    AASLD: Concomitant Medication Use (drug interactions) in Patients with Hepatitis C Genotype 1 Treated with Boceprevir Combination Therapy - (11/15/11)

    AASLD: A US-Based Cost-Effectiveness Analysis of Boceprevir-Based Regimens in Previously Untreated Adult Subjects with Chronic Hepatitis C Genotype 1 - (11/16/11)

    AASLD: Safety and Efficacy of Vaniprevir (MK-7009) in Combination with Peg-interferon a-2a (Peg-IFN)/Ribavirin (RBV) in Genotype 1 Treatment-Experienced HCV-Infected Japanese Patients - (11/16/11)

    AASLD: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship for MK-5172, a Novel Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, in Genotype 1 and Genotype 3 HCV-Infected Patients - (11/16/11)

    AASLD: Treatment-Na´ve Black Patients Treated with Boceprevir (BOC) Combined with Peginterferon alfa-2b + Ribavirin (PR): Results from HCV SPRINT-2 - (11/16/11)

    AASLD: Analysis of Resistance-Associated Amino Acid Variants (RAVs) in non-SVR Patients Enrolled in a Retrospective Long-term Follow-up Analysis of Boceprevir Phase 3 Clinical Studies - (11/15/11)

    AASLD: Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Prior Relapsers And Nonresponders - (11/15/11)

    AASLD: The Effect of Using Lower Limit of Quantitation (LLQ) vs Lower Limit of Detection (LLD) for the Definition of Undetectable HCV RNA: Data from the RESPOND-2 and SPRINT-2 trials - (11/15/11)

    AASLD: Predictors of Sustained Virologic Response Among Poor Interferon Responders When Boceprevir is Added to Peginterferon alfa-2b/Ribavirin - (11/15/11)

    62th Annual Meeting of the American Association for the Study of Liver Diseases
    San Francisco
    2011 Nov 6-9